Ollin Biosciences Raises $330M Series B to Advance Next-Generation Eye Disease Therapies

Ollin Biosciences is an Austin, Texas-based clinical-stage biopharmaceutical company that has raised an oversubscribed $330M Series B co-led by TCGX and ARCH Venture Partners. The financing will fund global Phase 3 development of OLN324 for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), while advancing OLN102 into clinical development for thyroid eye disease (TED) and Graves' disease.

The round brings Ollin Biosciences' disclosed funding to at least $430M since launching with $100M in 2025. More importantly, it signals continued investor confidence in companies building around validated biology, disciplined clinical execution, and meaningful therapeutic differentiation.

---

What Happened

The old saying is that the eyes are the window to the soul. In biotech, they're also one of the hardest frontiers to protect. Vision is unforgiving. Patients do not care how elegant the science looks in a slide deck if the therapy cannot preserve what matters when the lights come on tomorrow morning. That's why ophthalmology remains one of the toughest proving grounds in medicine. Biology does not negotiate, and decades of innovation have shown that every clinical milestone must be earned.

That is exactly why Ollin Biosciences raising an oversubscribed $330M Series B deserves attention. TCGX and ARCH Venture Partners co-led the round, joined by a16z Bio + Health, Blackstone Multi-Asset Investing, Commodore Capital, CPP Investments, RA Capital Management, accounts advised by T. Rowe Price Investment Management, an unnamed sovereign wealth fund, and returning investors Mubadala Capital and Monograph Capital. That's experienced capital backing therapies where better patient outcomes can change lives.

---

Why This Matters

Behind that momentum is a leadership team built for execution. Co-Founder and CEO Jason Ehrlich, M.D., Ph.D. works alongside co-founders Jason Coloma, Ph.D., CEO of Maze Therapeutics; Travis Murdoch, M.D., CEO of Braveheart Bio and former CEO of HI-Bio; and Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics.

Supporting that effort are Brian Cuneo, J.D., CXO/CLO; Florence Lorget, Pharm.D., Ph.D., SVP, Translational Research & Development Sciences; Andy Peterson, Ph.D., SVP, Biology; Varun Malhotra, M.D., M.B.A., VP, Clinical Development; Alexandra Haagensen, M.D., M.B.A., VP, Clinical Development; Pam Henderson, RN, B.S.N., VP, Clinical Operations; Will Liu, M.H.A., VP, Portfolio and Program; and Jonathan Kim, VP, Corporate Development. Biotech breakthroughs rarely arrive because of a single experiment. They emerge from years of disciplined execution across science, clinical development, operations, and capital allocation. Funding rounds may capture headlines, but the real story is usually the team that quietly built enough credibility for investors to commit hundreds of millions of dollars.

---

Market Context

The company launched with $100M and has now raised at least $430M to advance OLN324 into global Phase 3 studies for diabetic macular edema and wet age-related macular degeneration while moving OLN102 toward the clinic for thyroid eye disease and Graves' disease.

OLN324 is a next-generation VEGF/Ang2 bispecific antibody designed to improve treatment outcomes for retinal diseases, while OLN102 is being developed through a dual-target bispecific antibody approach targeting thyroid eye disease and Graves' disease. Both programs build on validated biology instead of unproven mechanisms, reducing scientific uncertainty while pursuing meaningful clinical improvements.

According to Ollin Biosciences, the retina market represents an approximately $15B opportunity, but commercial opportunity alone never guarantees success. Clinical data, regulatory execution, physician adoption, and long-term patient outcomes ultimately determine which therapies become standards of care.

---

What This Signals

Every funding round carries a signal beyond the headline number. This financing suggests investors continue rewarding companies that combine experienced leadership, disciplined clinical development, and differentiated therapeutic assets instead of chasing whatever happens to dominate biotech conversations that quarter.

For founders, investors, and operators watching healthcare innovation, the lesson is straightforward. Capital continues flowing toward companies capable of demonstrating scientific credibility, operational discipline, and clear regulatory pathways. Those qualities remain far more durable than hype because markets eventually separate compelling stories from measurable execution.

---